Targeting FSP1 triggers ferroptosis in lung cancer

Area of Science:

• Oncology
• Cell Death Mechanisms
• Biochemistry

Background:

• Ferroptosis, a form of regulated cell death, is triggered by lipid peroxidation and is being explored as an anti-cancer strategy.
• The role of ferroptosis as a barrier to tumorigenesis and its therapeutic potential remain unclear.
• GPX4 and ferroptosis suppressor protein 1 (FSP1) are key regulators of ferroptosis.

Purpose of the Study:

• To investigate the role of ferroptosis suppressors GPX4 and FSP1 in lung adenocarcinoma.
• To determine if ferroptosis can be therapeutically leveraged against lung tumors.
• To evaluate FSP1 as a potential therapeutic target in lung cancer.

Main Methods:

• Genetically engineered mouse models of lung adenocarcinoma were used for tumor-specific loss-of-function studies.
• GPX4 and FSP1 were genetically inhibited to assess their impact on tumorigenesis.
• Lipidomic analyses and various ferroptosis inhibition strategies (genetic, dietary, pharmacological) were employed.

Main Results:

• Loss of GPX4 or FSP1 led to increased lipid peroxidation and suppressed lung adenocarcinoma growth, indicating tumor sensitivity to ferroptosis.
• FSP1 was crucial for ferroptosis protection in vivo but not in vitro.
• Inhibition of ferroptosis restored tumor growth in Fsp1-knockout models.
• FSP1 expression correlated with poorer survival in lung adenocarcinoma patients.
• Pharmacologic inhibition of FSP1 demonstrated significant therapeutic benefits in preclinical models.

Conclusions:

• Lung tumors are highly sensitive to ferroptosis, and its suppression is critical in vivo.
• FSP1 is a key ferroptosis suppressor in vivo and a potential therapeutic target for lung cancer.
• FSP1 inhibition represents a promising therapeutic strategy for lung cancer treatment.